Get started
Author

Silvia Ferrari

Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity
2006 · Silvia Ferrari, Friedrich Scheiflinger, et al. · Blood · 295
IgG subclass distribution of anti‐ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura
2009 · S. FERRARI, G.C. MUDDE, et al. · Journal of Thrombosis and Haemostasis · 200
Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities
2020 · Chiara F. Magnani, Giuseppe Gaipa, et al. · Journal of Clinical Investigation · 195
PDF
von Willebrand factor cleaving protease (ADAMTS‐13) and ADAMTS‐13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura
2004 · Flora Peyvandi, Silvia Ferrari, et al. · British Journal of Haematology · 157
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study
2014 · A. Santoro, V. Gebbia, et al. · Annals of Oncology · 111
Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation
2005 · Barbara Plaimauer, Jakob Fuhrmann, et al. · Blood · 111
Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura
2013 · S. Ferrari, K. Palavra, et al. · Haematologica · 62
PDF
Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS‐13)
2008 · A. TRIPODI, F. PEYVANDI, et al. · Journal of Thrombosis and Haemostasis · 59
PDF
Vitamin K-Dependent Coagulation Factors That May be Responsible for Both Bleeding and Thrombosis (FII, FVII, and FIX)
2018 · Antonio Girolami, Silvia Ferrari, et al. · Clinical and Applied Thrombosis/Hemostasis · 51
Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies
2021 · Silvia Ferrari, Chiara Caprioli, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 39
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
2016 · Federico Cappuzzo, Alessandro Morabito, et al. · Lung Cancer · 38
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
2024 · Annalisa Chiappella, Beatrice Casadei, et al. · Leukemia · 35
PDF
Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients
2014 · Cesare Gridelli, Silvia Novello, et al. · Journal of Thoracic Oncology · 31
PDF
Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel)
2016 · Chiara Cattaneo, P. Zappasodi, et al. · Annals of Hematology · 28
Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 −/− epithelial ovarian cancers
2006 · Stefano Indraccolo, Veronica Tisato, et al. · European Journal of Cancer · 28
Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
2022 · Anas Younes, John M. Burke, et al. · Blood Advances · 26
PDF
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma
2020 · Leo I. Gordon, Jason B. Kaplan, et al. · Clinical Cancer Research · 25
Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study
2019 · Anas Younes, John M Burke, et al. · Blood · 24
Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients.
2005 · Silvia Ferrari, Fabio Malugani, et al. · PubMed · 24
Inverse correlation of free and immune complex‐sequestered anti‐ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura
2011 · S. FERRARI, P. KNÖBL, et al. · Journal of Thrombosis and Haemostasis · 23
PDF
Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study
2021 · Jean-Marie Michot, Julio C. Chavez, et al. · Blood · 21
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation
2025 · Federico Lussana, Chiara F. Magnani, et al. · Blood Cancer Journal · 19
PDF
Thrombotic thrombocytopenic purpura in IgG4‐related disease with severe deficiency of ADAMTS‐13 activity and IgG4 autoantibody against ADAMTS‐13
2011 · Takako Saeki, Tomoyuki Ito, et al. · Arthritis Care & Research · 16
Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy
2018 · Giuseppe Gritti, Andrea Gianatti, et al. · Oncotarget · 15
PDF
Electrical impedance tomography in children with community acquired pneumonia: preliminary data
2017 · Marta B. Mazzoni, Alessandra Perri, et al. · Respiratory Medicine · 15
PDF
Works count: 113
Citation count: 1,906
H-index: 21
I10-index: 36
Year
Topic
Type